Physicians classify brain tumors and determine treatment options, in part, by the genes they express. According to World ...

A review paper published last year in European Journal of Medicinal Chemistry characterized Myc as the “oncogene from ...

Physicians classify brain tumors and determine treatment options, in part, by the genes they express. According to World Health Organization standards, the abnormal activation of oncogene FOXR2 only ...

Physicians classify brain tumors and determine treatment options, in part, by the genes they express. According to World ...

The incidence of Human Papillomavirus (HPV)–associated oropharyngeal cancers—tumors of the back of the mouth and throat—is ...

Nurix is eligible for an additional $420 million in development, regulatory and commercial milestones associated with the ...

Array Bridge is testing promising drug candidates that can effectively bind and even degrade target proteins, but not via ...

NX-5948 assigned the nonproprietary name “bexobrutideg”U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström ...

Adcendo, a biotech company pioneering the development of first- and potential best-in-class antibody-drug conjugates (ADCs) for cancers with a high unmet medical need, today announced two important ...

The company granted stock options to purchase an aggregate of 79,950 shares of Nurix common stock and restricted stock unit ...